TEVA - Teva Pharmaceutical Industries Limited
NEXT EARNINGS:
May 6, 2026
EPS Est: $0.59
|
Rev Est: $3.9B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
Market Cap:
38.90B
Volume:
2,504,940
Avg Volume:
9,970,760
52 Week Range:
12.47-37.35
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Beta:
0.72
Last Dividend:
$N/A
Exchange:
NYSE
Country:
IL
Employees:
37,000
IPO Date:
1982-02-16
EPS (TTM):
1.23
P/E Ratio:
-15.21
Revenue (TTM):
17.26B
Total Assets:
40.75B
Total Debt:
17.38B
Cash & Equiv:
3.56B
Rev Growth (5Y):
-0.4%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
37.4%
ROCE:
7.8%
Debt/Equity:
3.36
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-01-28 | $0.96 | $0.65 | +47.7% | $4.7B | $3.9B | +21.7% |
| 2025-11-05 | $0.78 | $0.68 | +14.7% | $4.5B | $4.5B | +0.6% |
| 2025-07-30 | $0.66 | $0.63 | +4.8% | $4.2B | $4.4B | -4.3% |
| 2025-05-07 | $0.52 | $0.47 | +10.6% | $3.9B | $4.4B | -11.2% |
| 2025-01-29 | $0.71 | $0.69 | +2.9% | $4.2B | $4.1B | +3.0% |
| 2024-11-06 | $0.69 | $0.65 | +6.2% | $4.3B | $4.1B | +5.2% |
| 2024-07-31 | $0.61 | $0.57 | +7.0% | $4.2B | $4.1B | +1.6% |
| 2024-05-08 | $0.48 | $0.51 | -5.9% | $3.8B | $3.7B | +2.7% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.26B | 16.54B | 15.85B | 14.93B | 15.88B | 16.66B | 16.89B | 18.85B | 22.39B | 21.90B | 19.65B | 20.27B |
| Net Income | 1.41B | (1.64B) | (559.00M) | (2.45B) | 417.00M | (3.99B) | (999.00M) | (2.15B) | (16.27B) | 329.00M | 1.59B | 3.06B |
| EPS | 1.23 | -1.45 | -0.50 | -2.20 | 0.38 | -3.64 | -0.92 | -2.11 | -16.01 | 0.07 | 1.84 | 3.58 |
| Total Assets | 40.75B | 39.33B | 43.48B | 44.01B | 47.67B | 50.64B | 57.47B | 60.68B | 70.61B | 92.89B | 54.26B | 46.42B |
| Total Debt | 17.38B | 18.08B | 20.15B | 21.56B | 23.46B | 26.40B | 27.34B | 28.92B | 32.48B | 35.80B | 9.97B | 10.33B |
| Cash & Equivalents | 3.56B | 3.30B | 3.23B | 2.80B | 2.17B | 2.18B | 1.98B | 1.78B | 963.00M | 988.00M | 6.95B | 2.23B |
| Operating Cash Flow | 1.65B | 2.55B | 1.37B | 1.59B | 798.00M | 1.22B | 538.00M | 2.45B | 3.51B | 5.22B | 5.54B | 5.13B |
| Free Cash Flow | 1.15B | 2.05B | 842.00M | 1.04B | 236.00M | 638.00M | 419.00M | 1.79B | 2.63B | 4.32B | 4.77B | 4.20B |
| FCF per Share | 1.00 | 1.81 | 0.75 | 0.94 | 0.21 | 0.58 | 0.38 | 1.76 | 2.59 | 4.53 | 5.58 | 4.92 |
| Book Value | 7.91B | 5.37B | 7.51B | 7.80B | 10.28B | 10.03B | 13.97B | 14.71B | 17.36B | 33.34B | 29.77B | 23.31B |
| Cash & ST Investments | 3.56B | 3.30B | 3.23B | 2.80B | 2.17B | 2.18B | 1.98B | 1.78B | 963.00M | 988.00M | 6.95B | 2.23B |
| ROC Equity | 0.18 | -0.31 | -0.07 | -0.31 | 0.04 | -0.40 | -0.07 | -0.15 | -0.94 | 0.01 | 0.05 | 0.13 |